Loading clinical trials...

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment | Clinical Trials | Clareo Health

COMPLETEDNA

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

A Randomized, Double-Blind, Phase 2a Study to Evaluate the Tolerability, Feasibility, and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment Associated With End-Stage Renal Disease

NCT04527328•Alkahest, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.

Detailed Description

In this study, approximately 26 men and women on dialysis due to end stage renal disease and who have cognitive impairment will be randomly assigned to receive AKST1210 or control during each hemodialysis session for 3 months. The primary objective is to assess the safety and tolerability of AKST1210, and secondary objectives include changes in cognitive assessments as well as the feasibility of using AKST1210 in this setting.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•On chronic hemodialysis due to end-stage renal disease for ≥ 12 months.
•Score on the Montreal Cognitive Assessment (MoCA) ≥ 16 and ≤ 23.
•Body mass index (BMI) ≥ 20 and ≤ 36.
•The subject must be able to follow the study protocol, receive the treatment in the established timeframe, and continue during the follow-up interval.
•The subject must have sufficient visual and auditory acuity to reliably complete all study assessments.
•Provided a signed and dated informed consent form.

Exclusion Criteria

•Subjects for whom adequate anticoagulation cannot be achieved. Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is allowed.
•History of hypersensitivity to heparin.
•Pregnant or breast-feeding women or women who are planning to become pregnant.
•Clinically significant abnormalities on Screening ECG including QT interval corrected for heart rate (QTc) (using Fridericia's correction formula) of ≥ 500 ms in men and ≥ 520 ms in women.
•Clinically significant and unexpected abnormalities in this patient population in complete blood count, complete metabolic panel, coagulation, and thyroid stimulating hormone (TSH).
•Subjects with a hemoglobin level \< 9.0 g/dL.
•Concurrent or recent participation in another investigational clinical trial. Prior clinical trial subjects must have discontinued investigational agents at least 30 days prior to Screening.
•Subjects planning to receive renal transplantation during the study.
•Any other condition and/or situation that the investigator believes may interfere with the safety of the subject, study conduct, or interpretation of study data.

Locations (4)

Renal Consultants Medical Group

Granada Hills, California, United States

Valley Renal Medical Group

Northridge, California, United States

Orlando Clinical Research Center

Orlando, Florida, United States

US Renal Care Kidney Research

San Antonio, Texas, United States

Key Dates

Start Date

April 28, 2020

Primary Completion Date

June 4, 2021

Completion Date

June 4, 2021

Last Updated

December 12, 2022

Enrollment

ACTUAL participants

Conditions

Cognitive ImpairmentEnd Stage Renal Disease

Interventions

AKST1210

DEVICE

Sham Control (No Intervention)

OTHER

Hemodialysis

PROCEDURE

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGNA

Choline to Improve Malnutrition and Enhance Cognition

NCT06154174

Severe Acute MalnutritionCognitive Impairment+2 more

View study

RECRUITINGEARLY_PHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

Choline to Improve Malnutrition and Enhance Cognition

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors